Skip to main navigation menu Skip to main content Skip to site footer
##common.pageHeaderLogo.altText##

Original article

Vol. 147 No. 1920 (2017)

Severe injection site reactions after subcutaneous administration of Sayana®: a retrospective, post-marketing analysis of WHO and Swiss spontaneous pharmacovigilance reports

DOI
https://doi.org/10.4414/smw.2017.14432
Cite this as:
Swiss Med Wkly. 2017;147:w14432
Published
10.05.2017

Summary

PURPOSE

Sayana® was introduced as the first depot medroxyprogesterone acetate-containing contraceptive that is administered via subcutaneous injection. Within 10 months, the Regional Pharmacovigilance Centre (RPVC) Zurich received several anonymous reports of serious local reactions after Sayana® administration. In this retrospective study, individual case safety reports (ICSRs) on local adverse drug reactions (ADRs) related to Sayana® were analysed from the WHO pharmacovigilance database.

METHODS

International, national and regional ICSRs during Sayana® administration up to 1 January 2016 were examined. Data on ADRs were retrieved from the WHO Global Database VigiBase™. Demographic data, drug administration information, duration of Sayana® treatment, latency time of the ADR, and its course, severity and outcomes were analysed.

RESULTS

Worldwide, 398 ICSRs after Sayana® use were registered in the database. We identified 20 reported terms that were potentially used to describe a persistent lipodystrophy. When only cases containing one or more of these 20 reported terms were selected, 323 (81.2%) international ICSRs remained for analysis. Of those, 91.6% (n = 296) were categorised as serious. The majority of the reactions (n = 193, 54.4%) did not recover. In the 67 Swiss ICSRs, 77 ADRs were reported using 10 different terms including severe or persistent local reactions like lipodystrophy, atrophy or fat necrosis. Thirty-two patients (47.7%) did not recover. All 11 regional cases reported to the RPVC Zurich were categorised as serious ADRs. For the majority of the patients (n = 7, 63.6%) the interval between the application of Sayana® and development of the lipodystrophy was between 2 and 4 months. Most of the reactions were irreversible (n = 9, 81.8%). One patient underwent plastic surgery for artificial infill of the dent.

CONCLUSIONS

Persistent local injection site reactions such as lipodystrophy, fat tissue necrosis or atrophy occur frequently after subcutaneous Sayana® use. These adverse drug reactions were recently integrated in the Swiss product information. Physicians and patients should be informed and advised about these potentially irreversible effects.

References

  1. Royer PA, Jones KP. Progestins for contraception: modern delivery systems and novel formulations. Clin Obstet Gynecol. 2014;57(4):644–58. https://doi.org/10.1097/GRF.0000000000000072
  2. Product Information Sayana©, Pfizer AG, available from www.swissmedicinfo.ch, [updated Oct. 2014, accessed 2015-09-16].
  3. Dragoman MV, Gaffield ME. The safety of subcutaneously administered depot medroxyprogesterone acetate (104mg/0.65mL): A systematic review. Contraception. 2016;94(3):202–15. https://doi.org/10.1016/j.contraception.2016.02.003
  4. Swissmedic. Arzneimittel Statistik. Swissmedic Journal. 2012;4:347.
  5. Cameron ST, Glasier A, Johnstone A. Pilot study of home self-administration of subcutaneous depo-medroxyprogesterone acetate for contraception. Contraception. 2012;85(5):458–64. https://doi.org/10.1016/j.contraception.2011.10.002
  6. Prabhakaran S, Sweet A. Self-administration of subcutaneous depot medroxyprogesterone acetate for contraception: feasibility and acceptability. Contraception. 2012;85(5):453–7. https://doi.org/10.1016/j.contraception.2011.09.015
  7. Uppsala Monitoring Centre. VigiLyze. https://vigilyze.who-umc.org/. (accessed 2016-01-01).
  8. Swissmedic [Internet]. Market Surveillance, Pharmacovigilance. Available from https://www.swissmedic.ch/marktueberwachung/00135/00160/index.html?lang=en (accessed 2016-05-29).
  9. Micromedex® (Healthcare Series), (electronic version). Truven Health Analytics, Greenwood Village, Colorado, USA. Available at: http://www.micromedexsolutions.com/ (accessed 2015-09-16).
  10. Jain J, Jakimiuk AJ, Bode FR, Ross D, Kaunitz AM. Contraceptive efficacy and safety of DMPA-SC. Contraception. 2004;70(4):269–75. https://doi.org/10.1016/j.contraception.2004.06.011
  11. Product Information Depo-Provera© 150, Pfizer AG [Internet], available from www.swissmedicinfo.ch, [updated Oct. 2014, accessed 2016-05-29].
  12. Kaunitz AM, Darney PD, Ross D, Wolter KD, Speroff L. Subcutaneous DMPA vs. intramuscular DMPA: a 2-year randomized study of contraceptive efficacy and bone mineral density. Contraception. 2009;80(1):7–17. https://doi.org/10.1016/j.contraception.2009.02.005
  13. Dorai V, Hazard MC, Paris J, Delansorne R. Lipolytic activity of progesterone and synthetic progestins on rat parametrial adipocytes in vitro. J Pharmacol Exp Ther. 1991;258(2):620–5.
  14. Hazell L, Shakir SA. Under-reporting of adverse drug reactions : a systematic review. Drug Saf. 2006;29(5):385–96. https://doi.org/10.2165/00002018-200629050-00003

Most read articles by the same author(s)